Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | VNN1 | O95497 | 3/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.45 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20489500 | 0.86 | MAPT (0.57) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL20489451 | 0.82 | KMT2A (0.52) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL20489430 | 0.80 | NPC1 (0.51) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL19641240 | 0.80 | LMNA (0.49) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL30677194 | 0.80 | LMNA (0.49) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL23612318 | 0.80 | NPC1 (0.51) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL30059687 | 0.80 | NPC1 (0.51) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL31240859 | 0.79 | NPC1 (0.48) | NPC1RAB9AKMT2AMAPTLMNA | |
| SCHEMBL19641334 | 0.79 | NPC1 (0.51) | NPC1RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL20489508 | 0.79 | CLK4 (0.48) | NPC1RAB9AKMT2AHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | NPC1 730/4885RAB9A 3109/4885KMT2A 91/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | NPC1 707/4885RAB9A 3634/4885KMT2A 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.